Document is current
Any future updates will be listed below
-
Authors
Carvelli, Julien
Demaria, Olivier
Vély, Frédéric
Batista, Luciana
Chouaki Benmansour, Nassima
Fares, Joanna
Carpentier, Sabrina
Thibult, Marie-Laure
Morel, Ariane
Remark, Romain
André, Pascale
Represa, Agnès
Piperoglou, Christelle
,
Assante Miranda, Laura
Baron, William
Belaid, Nourhène
Caillet, Clarisse
Caraguel, Flavien
Carrette, Barbara
Carrette, Florent
Chanuc, Fabien
Courtois, Rachel
Fenis, Aurore
Giordano, Marilyn
Girard-Madoux, Mathilde
Giraudon-Paoli, Marc
Gourdin, Nicolas
Grondin, Gwendoline
Guillot, Franceline
Habif, Guillaume
Jaubert, Solène
Lopez, Julie
Le Van, Mélanie
Lovera, Naouel
Mansuy, Marine
Bonnet, Elodie
Sansaloni, Audrey
Reboul, Annick
Mitry, Emmanuel
Nekkar-Constant, Camille
Péri, Valentine
Ricaut, Paul
Simon, Léa
Vallier, Jean-Baptiste
Vétizou, Marie
Zerbib, Robert
,
Ugolini, Sophie
Etiennot, Marion
Galluso, Justine
Lyonnet, Luc
Forel, Jean-Marie
Papazian, Laurent
Velly, Lionel
André, Baptiste
Briantais, Antoine
Faucher, Benoit
Jean, Estelle
Seguier, Julie
Veit, Veronique
Harlé, Jean-Robert
Pastorino, Boris
Delteil, Clémence
Daniel, Laurent
Boudsocq, Jean-Paul
Clerc, Axelle
Delmond, Emmanuel
Vidal, Pierre-Olivier
Savini, Hélène
Coutard, Bruno
Cordier, Pierre Yves
Le Dault, Erwan
Guervilly, Christophe
Simeone, Pierre https://orcid.org/0000-0002-0682-9405
Gainnier, Marc
Morel, Yannis
Ebbo, Mikael
Schleinitz, Nicolas
Vivier, Eric https://orcid.org/0000-0001-7022-8287
- License Information
-
More Information
Article History
Received: 29 April 2020
Accepted: 23 July 2020
First Online: 29 July 2020
Competing interests
: O.D., L.B., J.F., S.C., M.-L.T., A.M., R.R., P.A., A.Represa, L.A.M., W.B., N.B., C.C., F. Caraguel, B.Carrette, F.Carrette, F.Chanuc, R.C., A.F., M.Giordano, M.G.-M., M.G.-P., N.G., G.G., F.G., G.H., S.J., J.L., M.L.V., N.L., M.M., E.B., A.S., A.Reboul, E.M., C.N.-C., V.P., P.R., L.S., J.-B.V., M.V., R.Z., Y.M. and E.V. are employees of Innate Pharma. The other authors declare no competing interests.
Free to read: This content has been made available to all.
